scPharmaceuticals Inc
SCPH5.240USD
+0.070+1.35%
시장 운영 시간 （ET）시세는 15분 지연됩니다
263.49M시가총액
손실P/E TTM
자세한 내용은 scPharmaceuticals Inc 회사
scPharmaceuticals Inc. is a pharmaceutical company. The Company is focused on developing and commercializing products to optimize the delivery of infused therapies, advance patient care and reduce healthcare costs. The Company develops, internally and through strategic partnerships, products and solutions that aim to expand and advance the outpatient care of select acute conditions. Its lead product candidate, FUROSCIX, consists of its formulation of furosemide delivered via an on-body infuser. FUROSCIX is a formulation of furosemide contained in a pre-filled, Crystal Zenith cartridge and self- administered subcutaneously via a single-use, disposable and wearable on-body delivery system. The Companay’s pipeline programs include SCP-111 (furosemide injection) 80mg/mL is an investigational pH neutral aqueous furosemide formulation that is being developed for subcutaneous administration outside of the hospital setting, including patient self-administration in the home.
회사 정보
종목 코드 SCPH
회사 이름scPharmaceuticals Inc
상장일Nov 17, 2017
CEOMr. John H. Tucker
직원 수162
유형Ordinary Share
회계 연도 종료Nov 17
주소25 Burlington Mall Road, Suite 203
도시BURLINGTON
증권 거래소NASDAQ Global Select Consolidated
국가United States of America
우편 번호01803
전화16175170730
웹사이트https://www.scpharmaceuticals.com/
종목 코드 SCPH
상장일Nov 17, 2017
CEOMr. John H. Tucker
회사 임원
이름
이름/직위
직위
주식 보유
변동
Mr. John H. Tucker
Mr. John H. Tucker
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
122.34K
-55.88%
Mr. Leonard D. Schaeffer
Mr. Leonard D. Schaeffer
Independent Director
Independent Director
111.90K
--
Ms. Rachael Nokes
Ms. Rachael Nokes
Chief Financial Officer
Chief Financial Officer
30.39K
-71.18%
Ms. Minnie Baylor-Henry, J.D.
Ms. Minnie Baylor-Henry, J.D.
Independent Director
Independent Director
--
--
Ms. Mette Kirstine Agger
Ms. Mette Kirstine Agger
Independent Director
Independent Director
--
--
Ms. Sara M. Bonstein
Ms. Sara M. Bonstein
Independent Director
Independent Director
--
--
Ms. Katherine Miranda
Ms. Katherine Miranda
Senior Manager - Corporate Communication
Senior Manager - Corporate Communication
--
--
Mr. Jack A. Khattar
Mr. Jack A. Khattar
Independent Chairman of the Board
Independent Chairman of the Board
--
-100.00%
Dr. Klaus Veitinger, M.D., Ph.D.
Dr. Klaus Veitinger, M.D., Ph.D.
Independent Director
Independent Director
--
--
Dr. William T. Abraham, M.D.
Dr. William T. Abraham, M.D.
Independent Director
Independent Director
--
--
더 보기
이름
이름/직위
직위
주식 보유
변동
Mr. John H. Tucker
Mr. John H. Tucker
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
122.34K
-55.88%
Mr. Leonard D. Schaeffer
Mr. Leonard D. Schaeffer
Independent Director
Independent Director
111.90K
--
Ms. Rachael Nokes
Ms. Rachael Nokes
Chief Financial Officer
Chief Financial Officer
30.39K
-71.18%
Ms. Minnie Baylor-Henry, J.D.
Ms. Minnie Baylor-Henry, J.D.
Independent Director
Independent Director
--
--
Ms. Mette Kirstine Agger
Ms. Mette Kirstine Agger
Independent Director
Independent Director
--
--
Ms. Sara M. Bonstein
Ms. Sara M. Bonstein
Independent Director
Independent Director
--
--
수익 분석
데이터 없음
데이터 없음
사업별
지역별
데이터 없음
주식 보유 통계
마지막 업데이트: Fri, May 16
마지막 업데이트: Fri, May 16
주주
주주 유형
주주
주주
비율
OrbiMed Advisors, LLC
11.48%
Rubric Capital Management LP
9.04%
Luther King Capital Management Corp.
6.95%
Lytton (Laurence W)
5.58%
AIGH Capital Management, LLC.
5.49%
Other
61.45%
주주
주주
비율
OrbiMed Advisors, LLC
11.48%
Rubric Capital Management LP
9.04%
Luther King Capital Management Corp.
6.95%
Lytton (Laurence W)
5.58%
AIGH Capital Management, LLC.
5.49%
Other
61.45%
주주 유형
주주
비율
Investment Advisor
26.77%
Private Equity
17.92%
Hedge Fund
15.19%
Investment Advisor/Hedge Fund
11.23%
Individual Investor
6.08%
Research Firm
3.79%
Venture Capital
2.27%
Bank and Trust
0.15%
Pension Fund
0.03%
Other
16.57%
기관 주식 보유
마지막 업데이트: Tue, Jul 1
마지막 업데이트: Tue, Jul 1
보고 기간
기관 수
보유 주식
비율
변동
2025Q2
207
44.05M
83.43%
-9.61M
2025Q1
220
46.17M
87.73%
-9.39M
2024Q4
216
48.09M
96.18%
-7.84M
2024Q3
205
45.54M
91.15%
-1.25M
2024Q2
187
32.09M
87.10%
-11.64M
2024Q1
180
29.20M
80.96%
-13.79M
2023Q4
174
29.67M
82.49%
-9.34M
2023Q3
165
32.24M
89.90%
-5.09M
2023Q2
160
30.81M
85.97%
-2.10M
2023Q1
135
26.76M
76.80%
-865.96K
더 보기
주주 활동
이름
보유 주식
비율
변동
Chg %
날짜
OrbiMed Advisors, LLC
6.06M
11.48%
--
--
Mar 31, 2025
Rubric Capital Management LP
4.78M
9.04%
--
--
Mar 31, 2025
Luther King Capital Management Corp.
3.12M
5.91%
+263.26K
+9.21%
Mar 31, 2025
Lytton (Laurence W)
2.94M
5.58%
+1.12M
+61.35%
Sep 30, 2024
AIGH Capital Management, LLC.
3.10M
5.86%
--
--
Mar 31, 2025
Lundbeckfond Invest
2.86M
5.42%
+2.86M
--
Sep 30, 2024
BlackRock Institutional Trust Company, N.A.
2.15M
4.08%
+43.64K
+2.07%
Mar 31, 2025
The Vanguard Group, Inc.
1.99M
3.77%
-115.70K
-5.49%
Mar 31, 2025
Morgan Stanley & Co. LLC
1.65M
3.12%
-29.52K
-1.76%
Mar 31, 2025
Rice Hall James & Associates, LLC
1.40M
2.65%
+408.42K
+41.27%
Mar 31, 2025
더 보기
관련 ETF
마지막 업데이트: Sat, Aug 2
마지막 업데이트: Sat, Aug 2
이름
비율
Invesco NASDAQ Future Gen 200 ETF
0.47%
iShares Micro-Cap ETF
0.03%
ProShares Ultra Nasdaq Biotechnology
0.02%
Invesco Nasdaq Biotechnology ETF
0.02%
Global X Russell 2000 ETF
0.01%
ProShares Hedge Replication ETF
0.01%
Proshares Ultra Russell 2000
0.01%
iShares Russell 2000 Growth ETF
0.01%
ProShares UltraPro Russell2000
0.01%
iShares Russell 3000 ETF
0%
더 보기
Invesco NASDAQ Future Gen 200 ETF
비율0.47%
iShares Micro-Cap ETF
비율0.03%
ProShares Ultra Nasdaq Biotechnology
비율0.02%
Invesco Nasdaq Biotechnology ETF
비율0.02%
Global X Russell 2000 ETF
비율0.01%
ProShares Hedge Replication ETF
비율0.01%
Proshares Ultra Russell 2000
비율0.01%
iShares Russell 2000 Growth ETF
비율0.01%
ProShares UltraPro Russell2000
비율0.01%
iShares Russell 3000 ETF
비율0%
주식 배당금
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.
날짜
배당금
기준일
지급일
배당락일
데이터 없음
주식 분할
날짜
유형
비율
데이터 없음
날짜
유형
비율
데이터 없음
